EIKO Lifesciences Intrinsic Value
EIKO Lifesciences (EIKO) median intrinsic value is ₹44.64 from 8 valuation models (range ₹24–₹69), vs current price ₹51.40 — -13.2% downside (Trading Above Median Value), margin of safety -15.1%. Browse EIKO financial statements for revenue, profit, balance sheet and cash flow data.
EIKO Valuation Methods Summary — DCF, Graham Number & P/E
EIKO Lifesciences intrinsic value across 8 models vs current price ₹51.40 — upside/downside and value range per method. For current market price and key ratios, visit EIKO share price.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹44.64 | ₹35.71 - ₹53.57 | -13.2% | EPS: ₹3.72, Sector P/E: 12x |
| Book Value Method | asset | ₹49.29 | ₹44.36 - ₹54.22 | -4.1% | Book Value/Share: ₹49.29, P/B: 1.0x |
| Revenue Multiple Method | revenue | ₹43.43 | ₹39.09 - ₹47.77 | -15.5% | Revenue/Share: ₹54.29, P/S: 0.8x |
| EBITDA Multiple Method | earnings | ₹34.29 | ₹30.86 - ₹37.72 | -33.3% | EBITDA: ₹8.00Cr, EV/EBITDA: 6x |
| PEG Ratio Method | growth | ₹23.81 | ₹21.43 - ₹26.19 | -53.7% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹30.65 | ₹27.59 - ₹33.72 | -40.4% | Revenue Growth: 6.0%, Adj P/E: 8.2x |
| ROE Based Valuation | profitability | ₹68.57 | ₹61.71 - ₹75.43 | +33.4% | ROE: 11.6%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹64.23 | ₹57.81 - ₹70.65 | +25.0% | EPS: ₹3.72, BVPS: ₹49.29 |
EIKO Intrinsic Value vs Market Price — All Valuation Models
EIKO Lifesciences fair value range ₹24–₹69 vs current market price ₹51.40 across 8 valuation models. Also explore EIKO stock price history to track price trends across different timeframes.
EIKO Intrinsic Value Analysis — Undervalued or Overvalued?
EIKO Lifesciences median intrinsic value ₹44.64, current price ₹51.40 — Trading Above Median Value by 13.2%, margin of safety -15.1%.
What is the intrinsic value of EIKO?
Based on our comprehensive analysis using 8 different valuation methods, the estimated intrinsic value of EIKO Lifesciences (EIKO) is ₹44.64 (median value). With the current market price of ₹51.40, this represents a -13.2% variance from our estimated fair value.
The valuation range spans from ₹23.81 to ₹68.57, indicating ₹23.81 - ₹68.57.
Is EIKO undervalued or overvalued?
Based on our multi-method analysis, EIKO Lifesciences (EIKO) appears to be trading above median value by approximately 13.2%.
EIKO Financial Health — Key Ratios vs Industry Benchmarks
EIKO Lifesciences financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 11.75 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 11.6% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | 12.0% | Industry Standard: 20%+ | Above 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.85x | Industry Standard: 1.0x+ | Above 0.5x | Measures asset utilization efficiency |
EIKO Cash Flow Quality — Operating & Free Cash Flow
EIKO Lifesciences operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹3 Cr | ₹-3 Cr | Positive Operating Cash Flow | 6/10 |
| March 2020 | ₹0 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |
| March 2019 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2018 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |
| March 2017 | ₹0 Cr | ₹0 Cr | Negative Cash Flow | 3/10 |